After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

M erck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...

Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...

Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the NSV indication.

The multi-centre, randomised, double-blind RUBY and TOPAZ studies are assessing the therapy’s performance against allopurinol ...

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

A small, early clinical trial led by the Icahn School of Medicine at Mount Sinai and collaborators has shown that directly ...

Artificial intelligence (AI) is rapidly transforming clinical trials by dramatically reducing timelines and costs, accelerating patient-centered drug development and creating more resilient and ...

An expert in gout clinical trials questions whether ethical considerations for such trials need updating to emphasize patient ...